摘要
目的探讨聚乙二醇化干扰素α-2a联合替诺福韦酯对耐药慢性乙肝患者肝功能及乙肝病毒的脱氧核糖核酸(HBVDNA)转阴率的影响。方法从2015年9月—2018年8月收治的耐药慢性乙肝患者中选取83例进行研究,以随机数字表法分为对照组41与观察组42例,对照组接受替诺福韦酯治疗,观察组在对照组基础上加聚乙二醇化干扰素α-2a,对两组治疗前后肝功能指标、血清病毒学指标、HBV-DNA转阴率进行观察。结果两组治疗前的谷草转氨酶(AST)、谷丙转氨酶(ALT)、总胆红素(TBIL)等肝功能指标差异无统计学意义(P>0.05),观察组治疗后的上述肝功能指标分别为(40.18±9.67)U/L、(42.61±15.37)U/L、(26.45±5.73)μmol/L,与对照组(51.49±8.42)U/L、(56.94±18.42)U/L、(37.42±6.84)μmol/L比较差异有统计学意义(t=5.677、3.851、7.928,P<0.05);两组治疗前的乙型肝炎E抗原(HBeAg)、HBV DNA及甲胎蛋白(AFP)等指标差异无统计学意义(P>0.05),观察组治疗后上述指标分别为(246.37±67.42)S/co、(3.72±1.13)log,IU/mL、(4.18±0.92)IU/mL,明显优于对照组(308.56±82.85)S/co、(4.59±1.28)log,IU/mL、(5.36±1.07)IU/mL(t=3.755、3.285、5.391,P<0.05);观察组治疗后HBV-DNA转阴率为78.57%,明显较对照组51.22%高(χ2=6.828,P<0.05)。结论聚乙二醇化干扰素α-2a联合替诺福韦酯可改善耐药慢性乙肝患者肝功能,也能控制其病毒水平,提高HBV-DNA转阴率,值得推广。
Objective To investigate the effect of pegylated interferonα2a combined with tenofovir on liver function and HBV-DNA negative rate in patients with drug-resistant chronic hepatitis B.Methods From September 2015 to August 2018,83 patients with drugresistant chronic hepatitis B were selected for retrospective analysis.according to the random number table method,it was divided into control group 41 and observation group 42 cases.The control group received tenofovir disoproxil,and the observation group added pegylated interferonα-2a to the control group.Liver function indicators,serum virological indicators,and HBV-DNA negative rate were observed before and after treatment.Results There were no statistically significant differences in liver function indexes between the two groups before treatment Aspartate aminotransferase(AST),alanine aminotransferase(ALT),total bilirubin(TBIL)(P>0.05).The above liver function indexes after treatment in the observation group were(40.18±9.67)U/L,(42.61±15.37)U/L,(26.45±5.73)μmol/L,and the control group(51.49±8.42)U/L,(56.94±18.42)U/L,(37.42±6.84)μmol/L were statistically significantly different(t=5.677,3.851,7.928,P<0.05);there were no statistically significant differences in serum viral markers such as hepatitis B E antigen(HBeAg),HBV DNA and alpha-fetoprotein(AFP)before treatment(P>0.05).The above indicators after treatment in the observation group were(246.37±67.42)S/co,(3.72±1.13)log,IU/mL,(4.18±0.92)IU/mL,which was significantly better than the control group(308.56±82.85)S/co,(4.59±1.28)log,IU/mL,(5.36±1.07)IU/mL(t=3.755,3.285,5.391,P<0.05);the conversion rate of HBV-DNA in the observation group was 78.57%,which was significantly higher than that of the control group 51.22%(χ2=6.828,P<0.05).Conclusion Pegylated interferonα-2a combined with tenofovir can improve liver function in patients with drug-resistant chronic hepatitis B,control viral levels,and increase HBV-DNA conversion rate,which is worthy of promotion.
作者
夏聘军
XIA Pin-jun(Department of Infectious Diseases,Central Hospital of Minxing District,Shanghai,201100 China)
出处
《世界复合医学》
2020年第2期174-176,共3页
World Journal of Complex Medicine
